NAMSA kondigt afstoting Sterility Assurance Products aan
NORTHWOOD, Ohio–(BUSINESS WIRE)– North American Science Associates, Inc. (NAMSA), ‘s werelds grootste organisatie in medisch onderzoek, is definitief akkoord met de afstoting van zijn divisie Sterility Assurance Products voor biologische en chemische indicatoren. Crosstex International, Inc.,dat zich richt op de levering van innovatieve producten ter preventie van infecties voor patiënten, zorgverleners en andere aanbieders binnen de gezondheidszorg, koopt de bedrijfsonderdelen van NAMSA’s divisie, waarmee het zijn aanbod op de industriële markt vergroot. De afstoting komt overeen met NAMSA’s strategische focus op preklinische en klinische diensten die de aanpak van een organisatie voor medisch onderzoek versterken. Dit zorgt voor een combinatie van advies op gebied van regelgeving en kwaliteit, laboratoriumtests en klinisch onderzoek, wat de tijd voor de vermarkting voor NAMSA’s cliënten verkort.
NAMSA Announces Divestiture of its Sterility Assurance Products Division |
|||||
|
NORTHWOOD, Ohio–(BUSINESS WIRE)– North American Science Associates, Inc. (NAMSA), the world’s leading medical research organization (MRO ®) today announced a definitive agreement to divest its Sterility Assurance Products Division of biological and chemical indicators. Crosstex International, Inc. (Crosstex), dedicated to delivering innovative infection prevention products for patients, caregivers, and other healthcare providers, will acquire the assets of NAMSA’s Products business to further expand their offerings in the industrial market. The divestiture is consistent with NAMSA’s strategy to focus the organization on preclinical and clinical services that support the MRO ® Approach, which offers a combination of regulatory and quality consulting, laboratory testing and clinical research to reduce time to market for its clients. As part of Crosstex, the industrial sterilization monitoring portfolio will be well positioned to continue to grow its global leadership position. This transaction will complement the biological monitoring portfolio of Crosstex, which is currently focused in the dental and medical markets. Crosstex will provide industrial clients sterilization monitoring products with the same level of service and support that they receive from NAMSA today with an expanded product offering. After the transaction closes, NAMSA will continue to manufacture sterilization monitoring products (for Crosstex) through the middle of 2016 depending on the product configuration, at which time Crosstex will integrate manufacturing into its global supply chain. Subject to customary closing conditions, NAMSA (and Crosstex) expect the transaction to close in the first quarter of 2016. About NAMSA NAMSA ( www.namsa.com) is the global medical research organization, providing comprehensive services to advise clients and evaluate the safety and efficacy of medical devices, IVDs and combination products. For nearly 50 years, NAMSA clients have utilized its consulting, testing and clinical services to bring safe and effective products to market. About Crosstex A Cantel Medical Corp. (NYSE:CMN); Crosstex ( www.crosstex.com) manufactures a wide array of unique and innovative infection prevention and control products for the global healthcare industry. Founded in 1953 and headquartered in Hauppauge, New York, Crosstex is a recognized leader for its portfolio of biological and chemical indicators, sterility assurance packaging and personal protection equipment (PPE). With the acquisition of SPSmedical in 2012 Crosstex further broadened and strengthened its position in the acute-care and alternate-care markets. Sold in more than 100 countries, the range of products distributed to medical, dental and veterinary practices and facilities include our award winning (5 consecutive years) Secure Fit technology face masks, DentaPure waterline treatment cartridges, Sure-Check sterilization pouches with internal/external multi-parameter indicators, Tyvek pouches with 510K approval, Steam Plus Type 5 chemical integrators, ConFirm and Passport Plus in-office and mail-in biological indicators, Rapicide OPA/28 high level disinfectant, intermediate level surface disinfectant spray and wipes, hand sanitizers, enzymatic detergent/cleaner, gloves and a full array of single-use disposables. View source version on businesswire.com: http://www.businesswire.com/news/home/20160203005204/en/ Contacts For further information about NAMSA or this news release, contact: |
|||||